 epipodophyllotoxin-rel leukemia identif new subset secondari leukemia thirty-seven children adult nonlymphocyt leukemia administr chemotherapi varieti hematolog solid malign secondari leukemia patient secondari leukemia treatment agent follow shorter latenc period predomin monocyt myelomonocyt featur frequent cytogenet abnorm patient epipodophyllotoxin risk secondari leukemia featur syndrom secondari leukemia agent